Sichuan Kelun-Biotech Directors Approve Full Circulation of H-Shares

MT Newswires Live06-21

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) directors approved the full circulation of up to 0.52% of the company's total H share count, according to a Thursday filing with the Hong Kong Stock Exchange.

Shares slid nearly 2% in Hong Kong on Friday afternoon.

Price (HKD): $172.10, Change: $-2.90, Percent Change: -1.66%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment